CLAIMS

1. A compound of formula (III) or a pharmaceutically acceptable salt thereof,



（III）

wherein

n is 0 or 1;

m is 1 or 2;

ring A is  or ;

T_1, T_2 and T_3 are each independently selected from N and CH;

E_1 is O, S or NH;

R_1 is selected from H and C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally substituted by 1, 2 or 3 R_a;

R_2 and R_3 are each independently selected from H, F, Cl, Br, I, OH, CN, NH_2 and C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally substituted by 1, 2 or 3 R_b;

R_4 is H;

R_5, R_6, R_7, R_8 and R_9 are each independently selected from H, F, Cl, Br, I, OH, CN, NH_2 and C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally substituted by 1, 2 or 3 R_c;

R_a, R_b and R_c are each independently selected from F, Cl, Br, I, OH, CN and NH_2.

2. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R_1 is selected from H and CH_3, wherein the CH_3 is optionally substituted by 1, 2 or 3 R_a.

3. The compound or pharmaceutically acceptable salt thereof according to claim 2, wherein R_1 is CH_3.

4. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R_2

and R_3 are each independently selected from H, F, Cl, Br, I, OH, CN, NH_2 and CH_3, wherein the CH_3 is optionally substituted by 1, 2 or 3 R_b.

5. The compound or pharmaceutically acceptable salt thereof according to claim 4, wherein R_2 and R_3 are each independently selected from H and CH_3.

6. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R_5, R_6, R_7, R_8 and R_9 are each independently selected from H, F, Cl, Br, I, OH, CN, NH_2, CH_3 and $-CH_2-CH_3$, wherein the CH_3 and $-CH_2-CH_3$ are optionally substituted by 1, 2 or 3 R_c.

7. The compound or pharmaceutically acceptable salt thereof according to claim 6, wherein R_5, R_6, R_7, R_8 and R_9 are each independently selected from H, F, Cl, Br, I, OH, CN and NH_2.

8. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the structural moiety  is ,  or .

9. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein ring A is  or .

10. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1-7, wherein the compound is selected from



（II）

or



（III-1）

wherein

m, n, E_1, T_1, T_2 and T_3 are as defined in claim 1;

R_1 is as defined in any one of claims 1-3;

R_2 and R_3 are as defined in claim 1, 4 or 5;

R_4 is as defined in claim 1;

R_5, R_6, R_7, R_8 and R_9 are as defined in claim 1, 6 or 7.

11. The compound or pharmaceutically acceptable salt thereof according to claim 10, wherein the compound is selected from



（III-2）



（III-3）

or



（III-4）

wherein

R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, E_1, T_1, T_2 and T_3 are as defined in claim 10.

12. The compound or pharmaceutically acceptable salt thereof according to claim 10, wherein the compound is selected from



（II-1）

wherein

R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, T_1, T_2 and T_3 are as defined in claim 10.

13. The compound or pharmaceutically acceptable salt thereof according to claim 12, wherein the compound is selected from



（I-1）

wherein

R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8 and R_9 are as defined in claim 10.

14. A compound represented by the following formula or a pharmaceutically acceptable salt thereof,













and



.

15. The compound or pharmaceutically acceptable salt thereof according to claim 14, wherein the compound is selected from  and .

16. Use of the compound or pharmaceutically acceptable salt thereof according to any one of claims 1-15 in the manufacture of a medicament for treating cancer.

17. The use according to claim 16, wherein the cancer is melanoma, BRAFV600E mutant non-small cell lung cancer, or colon cancer.

18. A medicament, comprising the compound or pharmaceutically acceptable salt thereof according to any one of claims 1-15.